BRPI0500959A - uso farmacológico de inibidor da expressão da proteìna coativador 1 alfa do receptor ativado por proliferador do peroxisoma (pgc-1(alfa)) para o tratamento de diabetes mellitus, resistência à insulina e sìndrome metabólica, seu composto e sua composição farmacêuticos - Google Patents

uso farmacológico de inibidor da expressão da proteìna coativador 1 alfa do receptor ativado por proliferador do peroxisoma (pgc-1(alfa)) para o tratamento de diabetes mellitus, resistência à insulina e sìndrome metabólica, seu composto e sua composição farmacêuticos

Info

Publication number
BRPI0500959A
BRPI0500959A BRPI0500959-6A BRPI0500959A BRPI0500959A BR PI0500959 A BRPI0500959 A BR PI0500959A BR PI0500959 A BRPI0500959 A BR PI0500959A BR PI0500959 A BRPI0500959 A BR PI0500959A
Authority
BR
Brazil
Prior art keywords
alpha
pgc
diabetes mellitus
activated receptor
glucose levels
Prior art date
Application number
BRPI0500959-6A
Other languages
English (en)
Inventor
Licio Augusto Velloso
Claudio Teodoro De Souza
Original Assignee
Unicamp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unicamp filed Critical Unicamp
Priority to BRPI0500959-6A priority Critical patent/BRPI0500959A/pt
Priority to EP06721614A priority patent/EP1879905A1/en
Priority to JP2008502196A priority patent/JP2008533178A/ja
Priority to CA002601855A priority patent/CA2601855A1/en
Priority to MX2007011705A priority patent/MX2007011705A/es
Priority to KR1020077024342A priority patent/KR20080005509A/ko
Priority to PCT/BR2006/000055 priority patent/WO2006099706A1/en
Priority to CNA2006800147334A priority patent/CN101166751A/zh
Priority to US11/909,323 priority patent/US20090029933A1/en
Publication of BRPI0500959A publication Critical patent/BRPI0500959A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USO FARMACOLóGICO DE INIBIDOR DA EXPRESSãO DA PROTEìNA COATIVADOR 1 ALFA DO RECEPTOR ATIVADO POR PROLIFERADOR DO PEROXISOMA (PGC-1<244>) PARA O TRATAMENTO DE DIABETES MELLITUS, RESISTêNCIA à INSULINA E SìNDROME METABóLICA, SEU COMPOSTO E SUA COMPOSIçãO FARMACêUTICOS". A presente invenção refere-se ao uso de um oligonucleotídeo de DNA antisense para a fita de RNA mensageiro para a proteína PGC-1<244>, útil como fármaco para tratamento de diabetes mellitus, resistência à insulina e síndrome metabólica. Mais especificamente, a presente invenção trata-se de um composto utilizado como fármaco, por via enteral ou parenteral, preferencialmente, com a propriedade de inibir a expressão da proteína Coativador 1 alfa do receptor ativado por proliferador do peroxisoma (PGC-1<244>). Levando à redução dos níveis sanguíneos de glicose. Trata-se, portanto, de um composto farmacológico que promove, em indivíduos diabéticos e resistentes à insulina, melhora dos níveis de glicose sérica, aumento da concentração de insulina plasmática e redução da resistência à insulina. A presente invenção apresenta um controle mais efetivo dos níveis de glicose e atua de forma benéfica sobre outras complicações associadas aos quadros de Diabetes e obesidade, como a esteatose hepática, segundo testes efetuados em modelos animais. Desta forma, a principal vantagem da presente invenção sobre similares já existentes no mercado é a efetividade com que controla níveis sanguíneos de glicose e o fato de atuar beneficamente em outras complicações que acompanham a doença.
BRPI0500959-6A 2005-03-23 2005-03-23 uso farmacológico de inibidor da expressão da proteìna coativador 1 alfa do receptor ativado por proliferador do peroxisoma (pgc-1(alfa)) para o tratamento de diabetes mellitus, resistência à insulina e sìndrome metabólica, seu composto e sua composição farmacêuticos BRPI0500959A (pt)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BRPI0500959-6A BRPI0500959A (pt) 2005-03-23 2005-03-23 uso farmacológico de inibidor da expressão da proteìna coativador 1 alfa do receptor ativado por proliferador do peroxisoma (pgc-1(alfa)) para o tratamento de diabetes mellitus, resistência à insulina e sìndrome metabólica, seu composto e sua composição farmacêuticos
EP06721614A EP1879905A1 (en) 2005-03-23 2006-03-20 Inhibitor of peroxisome proliferator-activated receptor alpha coactivator 1
JP2008502196A JP2008533178A (ja) 2005-03-23 2006-03-20 ペルオキシソーム増殖因子活性受容体αコアクチベーター１阻害剤
CA002601855A CA2601855A1 (en) 2005-03-23 2006-03-20 Inhibitor of peroxisome proliferator-activated receptor alpha coactivator 1
MX2007011705A MX2007011705A (es) 2005-03-23 2006-03-20 Inhibidor del coactivador 1 alfa del receptor activado por el proliferador de peroxisoma.
KR1020077024342A KR20080005509A (ko) 2005-03-23 2006-03-20 퍼옥시좀 증식제-활성화 수용체 알파 보조작용자 １의억제제
PCT/BR2006/000055 WO2006099706A1 (en) 2005-03-23 2006-03-20 Inhibitor of peroxisome proliferator-activated receptor alpha coactivator 1
CNA2006800147334A CN101166751A (zh) 2005-03-23 2006-03-20 过氧化物酶体增殖物-活化的受体α辅激活物1的抑制剂
US11/909,323 US20090029933A1 (en) 2005-03-23 2006-03-20 Inhibitor of peroxisome proliferator-activated receptor alpha coactivator 1

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0500959-6A BRPI0500959A (pt) 2005-03-23 2005-03-23 uso farmacológico de inibidor da expressão da proteìna coativador 1 alfa do receptor ativado por proliferador do peroxisoma (pgc-1(alfa)) para o tratamento de diabetes mellitus, resistência à insulina e sìndrome metabólica, seu composto e sua composição farmacêuticos

Publications (1)

Publication Number Publication Date
BRPI0500959A true BRPI0500959A (pt) 2006-11-21

Family

ID=37023323

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0500959-6A BRPI0500959A (pt) 2005-03-23 2005-03-23 uso farmacológico de inibidor da expressão da proteìna coativador 1 alfa do receptor ativado por proliferador do peroxisoma (pgc-1(alfa)) para o tratamento de diabetes mellitus, resistência à insulina e sìndrome metabólica, seu composto e sua composição farmacêuticos

Country Status (9)

Country Link
US (1) US20090029933A1 (pt)
EP (1) EP1879905A1 (pt)
JP (1) JP2008533178A (pt)
KR (1) KR20080005509A (pt)
CN (1) CN101166751A (pt)
BR (1) BRPI0500959A (pt)
CA (1) CA2601855A1 (pt)
MX (1) MX2007011705A (pt)
WO (1) WO2006099706A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2397889B1 (es) 2011-03-25 2014-02-07 Lipotec, S.A. PÉPTIDOS MODULADORES DE PGC-1Alfa.
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
AU2015339576B2 (en) 2014-10-27 2020-02-06 Glytec, Llc Subcutaneous outpatient management
AU2016308953B2 (en) 2015-08-20 2020-09-10 Glytec, Llc Diabetes management therapy advisor
KR101980576B1 (ko) 2017-07-06 2019-05-22 충남대학교산학협력단 PGC-1α를 포함하는 제2형 당뇨병 진단용 바이오마커

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2466415C (en) * 2001-11-09 2020-01-21 Dana-Farber Cancer Institute, Inc. Pgc-1.beta., a novel pgc-1 homologue and uses therefor

Also Published As

Publication number Publication date
MX2007011705A (es) 2007-12-12
WO2006099706A1 (en) 2006-09-28
CN101166751A (zh) 2008-04-23
JP2008533178A (ja) 2008-08-21
CA2601855A1 (en) 2006-09-28
US20090029933A1 (en) 2009-01-29
KR20080005509A (ko) 2008-01-14
EP1879905A1 (en) 2008-01-23

Similar Documents

Publication Publication Date Title
BRPI0500959A (pt) uso farmacológico de inibidor da expressão da proteìna coativador 1 alfa do receptor ativado por proliferador do peroxisoma (pgc-1(alfa)) para o tratamento de diabetes mellitus, resistência à insulina e sìndrome metabólica, seu composto e sua composição farmacêuticos
Pinney et al. Exendin-4 increases histone acetylase activity and reverses epigenetic modifications that silence Pdx1 in the intrauterine growth retarded rat
Duca et al. Metformin activates a duodenal Ampk–dependent pathway to lower hepatic glucose production in rats
Nosso et al. Comparative effects of Roux-en-Y gastric bypass and sleeve gastrectomy on glucose homeostasis and incretin hormones in obese type 2 diabetic patients: a one-year prospective study
Ropero et al. Bisphenol‐A disruption of the endocrine pancreas and blood glucose homeostasis
Pamir et al. Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis
Rodbard et al. Adding fast‐acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: a randomized, 18‐week, open‐label, phase 3 trial (onset 3)
Holst et al. Combining GLP‐1 receptor agonists with insulin: therapeutic rationales and clinical findings
Wysham et al. Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial
Rouabhia et al. Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism
Nilsson et al. Presence of contractile endothelin-A and dilatory endothelin-B receptors in human cerebral arteries
Vetter et al. Comparison of bariatric surgical procedures for diabetes remission: efficacy and mechanisms
Xue et al. NLRP3 promotes glioma cell proliferation and invasion via the interleukin-1β/NF-κB p65 signals
Penlioglou et al. COVID-19 and diabetes mellitus: May old anti-diabetic agents become the new philosopher’s stone?
NZ592283A (en) Combination of an insulin and the GLP-1 agonist AVE0010
BRPI0511703A (pt) composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o inìcio do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, sìndrome x, um distúrbio lipìdico, aterosclerose, e uma condição
MX2009006709A (es) Tratamiento de enfermedades relacionadas con il-1beta.
Schernthaner et al. Cure of type 2 diabetes by metabolic surgery? A critical analysis of the evidence in 2010
Tomlinson et al. The role of sulfonylureas in the treatment of type 2 diabetes
Kashyap et al. Clinical considerations for the management of residual diabetes following bariatric surgery
Patel et al. Central and peripheral glucagon reduces hyperlipidemia in rats and hamsters
Yamamoto et al. Potential mechanisms mediating improved glycemic control after bariatric/metabolic surgery
Ding et al. Glucose-dependent insulinotropic peptide stimulates thymidine incorporation in endothelial cells: role of endothelin-1
Huh et al. Predictors for successful weight reduction during treatment with Dapagliflozin among patients with type 2 diabetes mellitus in primary care
Ghaffari et al. Polyinosinic‐polycytidylic acid suppresses acetaminophen‐induced hepatotoxicity independent of type I interferons and toll‐like receptor 3

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Ipc: C12N 15/63 (2010.01), C12N 15/11 (2010.01), A61K 3

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C12N 15/11 (2006.01), C12N 15/63 (2006.01), A61K 3

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal: appeal against refusal